Astract. This study describes the effects of bezafibrate, an analogue of clofibrate, on the plasma lipid and lipoprotein profiles of 11 hypertriglyceridemic subjects and on their metabolism of apolipoproteins A-I, A-II, and B. The major action of the drug was to lower plasma triglyceride (by 58%; P < 0.01). This was accompanied by a reduction in the level of very low density lipoprotein apoprotein B (Svedberg units of flotation [Sf] , whose mean residence time in the plasma fell threefold (from 3.4 to 1.0 h). Synthesis of the B protein in this fraction was not significantly altered, so the drug acts to accelerate the transit of very low density lipoprotein particles down the delipidation cascade. The metabolism of very low density lipoprotein remnant apoprotein B (Sf 12-100) changed little in response to treatment, although we detected a 30% increment (P < 0.05) in the plasma concentration of this fraction. The mean residence time of these remnant particles in the plasma did not correlate with that of Sf 100-400 very low density lipoprotein apoprotein B, nor was this parameter altered by the drug. The most consistent and significant perturbation seen in the Sf 0-12 fraction (low density lipoprotein) was a reduction in the fractional catabolism of its apoprotein B moiety (26%; P < 0.05). In those subjects who were grossly hypertriglyceridemic and who responded well to treatment, the level of this protein rose substantially owing to a combined increase in its synthesis and a reduction Receivedfor publication 3 February 1983 and in revised form 18 July 1984. in its catabolism. In the group as a whole, high density lipoprotein cholesterol rose 13% (P < 0.02), and detailed examination showed that this was associated with a small but significant increment in the plasma concentration of the high density lipoprotein subfraption 2. High density lipoprotein subfraction 3 also rose on the average, but this was not a consistent feature in all patients. The plasma concentrations and turnovers of the A proteins (A-I and A-II) were not significantly altered by bezafibrate therapy.
Introduction
Recognition of the risk association between atherosclerosis and hyperlipidemia has led over the last two decades to the development of a number of agents designed to lower plasma cholesterol and triglyceride. Initially their efficacy was gauged simply on their hypolipemic effect, but increasing awareness of the complexity of lipoprotein metabolism has highlighted the need for a much more critical assessment of their mechanisms of action. We need to know how they affect the entire plasma lipoprotein spectrum and in particular we must determine their influence on those apoproteins that regulate lipid metabolism. Clofibrate was one of the earliest compounds exploited clinically to lower plasma lipid levels (1) . It effectively reduces plasma triglyceride (2, 3) but unfortunately also increases the lithogenic index of bile and predisposes to gallstone formation (4, 5, 6) . In addition, when it was used as a lipid lowering agent in two large clinical trials (2, 7), it had no effect on the rate of death from coronary artery disease and in fact may even have predisposed overall to an increase in mortality in the drug-treated subjects (7) . Recent (12) . The hypocholesterolemic action of bezafibrate may follow in part from its apparent ability to suppress 3-hydroxy-3-methylglutaryl Coenzyme A reductase activity, although so far this effect has only been demonstrated in rats (13) . The (9, 14, 16) . The greatest changes are seen in hypertriglyceridemic subjects whose initial HDL levels are low and who respond well to treatment. Since HDL apparently has a protective function that counteracts the detrimental influences of VLDL and LDL on atherogenesis, the overall merits of the drug must be assessed from its effects on these two lipoprotein families. The present work examines the impact of bezafibrate on apolipoprotein A and apolipoprotein B (apoB),' the major proteins found in these fractions. 1 . Abbreviations used in this paper: apoA-I, apoA-II, and apoB, apolipoproteins A-I, A-II and B, respectively; Sf, Study II: VLDL apoB metabolism. Here we examined the effects of bezafibrate on the metabolism of apolipoprotein B in its transit from VLDL through an intermediate fraction to LDL. These three fractions were isolated by a modification of the cumulative flotation ultracentrifugation procedure of Lindgren et al. (30) . The gradient employed was that originally described for the separation of LDL subfractions. Centrifugation times were adjusted to permit separation of fractions of Svedberg units of flotation (Sf) 100-400 (VLDL), 12-100, and 0-12 (LDL). The centrifugal force exerted during each of these sequential spins was 10.82 X 106, 92.88 X 106, and 120.6 X 106 g min, respectively. Plasma, isolated after a 14-h fast, was adjusted to a density of 1.118 kg/liter by the addition of 341 mg of NaCl to a 2.0-ml aliquot. This was placed over a 0.5-ml cushion of d = 1.182 kg/liter NaBr solution in a cellulose nitrate tube for the Beckman SW 40 rotor (Beckman Instruments Inc., Fullerton, CA) and overlayered with a discontinuous gradient from 1.0988 to 1.0588 kg/liter (30). The rotor was subjected to centrifugation at 37,000 rpm for 66 min and allowed to decelerate without braking. The top 1.0-ml fraction, containing VLDL, was removed with a Pasteur pipette and replaced by 1.0 ml ot d = 1.0588 g/ml solution. Centrifugation was repeated at 27,000 rpm for 17 h 36 min before removal of the intermediate fraction in 0.5 ml and then at 28,000 rpm for 21 h 12 min to isolated LDL in the upper 1.0 ml of the tube. All centrifugations were performed at 23°C. Chylomicrons, if present, were removed in a preliminary centrifugation at 10,000 rpm for 30 min in a Beckman 40.3 rotor (Beckman Instruments Inc.) (23°C). Recoveries of cholesterol were 98% of those obtained in d < 1.063 kg/liter lipoproteins prepared by standard procedures (21).
In the control phase of this study measurement was made of plasma lipid and lipoprotein levels (18) and of apolipoprotein B kinetics in the lipoproteins of S 100-400, 12-100, and 0-12 of six hypertriglyceridemic subjects (four Type IV and two Type V). To ensure constancy of dietary intake during both phases of the study, each subject was interviewed by a dietitian who prescribed and monitored his intake. Individual diets were formulated to be isocaloric with regular intake and provided 20% of the kilocalories as protein, 40% as carbohydrate, and 40% as fat. This regimen was followed for at least I wk before each phase of the study and throughout the turnover periods.
Blood was collected after a 14-h fast and the S$ 100-400 lipoprotein was isolated from 24 ml of plasma. The resultant 12-ml fraction (containing -0.05-5.0 mg protein) was concentrated if necessary by pressure filtration (XM 100 filters; Amicon Corp.) to a protein content of I mg/ml. It was then labeled as described previously (31) . Labeling efficiency was 5-10%, so an ICI/protein molar ratio of 20/1 (assuming an average protein molecular weight in VLDL of 300,000) resulted in the incorporation of -I mol of iodine per mole protein. Analysis of the labeled tracer showed that 20-30% of the radioactivity was extractable into 2:1 (vol/vol) chloroform methanol. Of the remainder, 40% was present in tetramethylurea precipitable protein. After labeling was done, the VLDL was dialyzed overnight against 0.15 M NaCl/0.01% Na2EDTA/0.01 M Tris (pH 7.0), sterilized by membrane filtration (0.45 um filters; Amicon Corp.), and injected at a dose of 20-40 #Ci into the bloodstream of the donor. All injections were made at 8:00 AM and the elapsed time between collection of the plasma for sample preparation and administration of the tracer was 24 h. Plasma samples were collected frequently over the first 72 h and then daily for 14 d. On the day of injection, the subject received at regular intervals 10 small meals of equal kilocalorie content which included his daily allowance of carbohydrate and protein, but <6 g of fat (i.e., he was hypocaloric for this day). This maneuver maintained the plasma VLDL apoB concentration at a value that did not show any tendency either to rise or to fall and whose coefficient of variation was < 15%.
The three lipoprotein fractions were prepared from each timed blood sample and the specific activity of their contained apoB was determined by a modification (31) of the method of Kane et al. (32) . When performed at 370C, this precipitation procedure sediments protein with the amino acid composition and sodium dodecyl sulfate gel electrophoretic behavior of apoB (31, 32) ; specifically, little apolipoprotein E appears in the precipitate. In subjects (like DH) whose plasma VLDL concentration was low, an approximately equivalent amount of unlabeled carrier VLDL was added to the isolated VLDL fraction before tetramethylurea precipitation. The patients' VLDL apoB concentration was then determined by difference (i.e., total protein -carrier). The pool size of apoB in the flotation ranges 100-400, 12-100, and 0-12 was calculated as the mean tetramethylureaprecipitable protein recovered in each fraction obtained from all fasting blood samples. The total apoB radioactivity in each fraction was thus determined at each time point and expressed as a fraction of the apoB activity present in the 10-min blood sample. Throughout the turnover period, variation in the plasma apoB concentration in the Sf 100-400, 12-100, and 0-12 fractions did not exceed 17, 15, and 12% of the mean value, suggesting that steady state conditions persisted. Plasma volume was taken to be 4% of the subjects' body weight. This gave values within 10% of the estimate obtained from the isotope dilution that occurred over the first 10 min after tracer injection.
ApoB kinetic analysis. The data obtained as described above were analyzed by a computer based multicompartmental modeling program similar to Simulated Analysis and Modeling (SAAM) (33) and NONLIN (34) . The algorithm employed in this study was built around subroutines2 2. Three subroutines were employed in the simulation and parameter estimation program. The first was D02BBF, which integrates a system of first-order ordinary differential equations over a range with suitable initial conditions by use of a Runge-Kutta-Merson method. Given a set of parameters, this generated a solution based on the mathematical model provided by the user in the form of a series of differential equations. The second subroutine, E04JAF was an easy-to-use quasiNewton algorithm for finding the minimum value of a function. This adjusted the parameters iteratively until a minimum weighted sum of commercially available from the Numerical Algorithms Group (Cambridge, England). The routines were incorporated into a simple Fortran program which permitted data input, model specification, and output of the final parameter values with their associated errors. The total apoB radioactivity present in the three flotation intervals was calculated by multiplying the measured specific activity and the appropriate plasma apoB pool size.
The model shown in Fig. 1 represents the simplest mamillary system that provided acceptable (i.e., unique and consistent [35] ) solutions for the parameters. When this system was used, the first order rate constants describing Sf 100-400, 12-100, and 0-12 apoB kinetics were obtained and these, together with the apoprotein pool sizes, permitted calculation (where appropriate) of steady state transfer rates of apoB between compartments. Overall fractional clearance rates for Sf 100-400 and 12-100 apoB were calculated from the relationships shown in Fig. 1 
Results
All subjects showed a hypotriglyceridemic response to bezafibrate therapy (Table I ). The reduction in the two Type V subjects was 53 and 80% (PK and VS, respectively), and the mean decrement in the nine others was 58% (P < 0.01). Overall, plasma cholesterol did not change significantly, but its distribution among the major lipoprotein fractions was altered. The level of the lipid in VLDL fell consistently (50%; P < 0.001) in proportion to the reduction in plasma triglyceride. The change in LDL cholesterol, on the other hand, was variable. In those subjects (e.g., AK, PK, VS) in whom it was initially subnormal and whose triglyceride levels were grossly elevated (i.e., >500 mg/dl), it rose. The other subjects, whose plasma triglyceride was moderately elevated and whose LDL cholesterol was within our reference range, failed to show any significant change. This is a characteristic response of hypertriglyceridemic individuals to clofibrate analogue therapy. The cholesterol content of the plasma HDL fraction rose by 13% (P < 0.02), but there was no obvious correlation by simple regression analysis between this change in any individual and his hypotriglyceridemic response.
Study I: effects of bezafibrate on HDL metabolism. In the group of eleven subjects, HDL cholesterol rose significantly (P < 0.02; Table I ) as a result of bezafibrate therapy. However, there was no change in plasma apoA-I and A-II concentrations (Table II) in the subjects examined in Study I. Determination of the HDL subfraction distribution in this group revealed squares was achieved. The radioactivity data for VLDL, IDL, and LDL apoB were weighted in the least squares fitting procedure according to their estimated errors (33) . This allowed calculation of the variance of the parameters, which were finally obtained (33, 34) using the third subroutine, FO 1 ADF, a matrix inversion procedure. A comparison was made between the parameters and their variances calculated for a set of VLDL apoB -LDL apoB decay curves analyzed by SAAM (31) and by the present algorithm. The parameter estimates were within 10% of each other and the variances, were within 20%. Fig. 2. In the normal subject, Sf 100-400 apoB was cleared monoexponentially and appeared virtually quantitatively in the Sf 12-100 flotation range (i.e., k1 was 0.006 h-' and k2 was 0.68 h-'; Fig. 1) . Thereafter, the decay of radioactivity from the latter was clearly biexponential. A similar pattern was noted in the Type IV subject although his fractional VLDL apoB clearance was slower (k, = 0.0 h-'; k2 = 0.13 h-'). Again, all VLDL apoB reached the intermediate density particle in this patient. In contrast to the above, the Type V subject cleared VLDL apoB biexponentially from his plasma, although, once inputs. In the kinetic analysis it was necessary to distribute the more, the transfer of VLDL apoB from pool 1 into Sf 12-100 mass of VLDL apoB between them. We did this, on the particles was complete (k1 = 0.007 h-'; k2 = 0.10 h-'). These assumption that the B protein in each pool was labeled to the features of VLDL apoB metabolism led to the formulation of same specific activity, by curve peeling the biexponential the model shown in Fig. 1 . Two VLDL apoB pools were VLDL apoB decay and extrapolating to zero time. The derived required to explain the biexponential nature of the decay curve intercepts then gave the distribution between the pools. Radioof this protein in grossly hypertriglyceridemic subjects, since, active apoB in compartment 1 was either lost directly from as discussed in previous publications (31, 38, 39) , VLDL the plasma or transferred into compartment 3. The model appears to be constrained as a result of its size to the plasma ( Fig. 1 in Sr 12-100 apoB radioactivity over the first 50 h was associated with a rise in the activity of LDL apoB, although this transit (Fig. 3 ) from intermediate to Sr 0-12 lipoproteins was incomplete, most apoB leaving the S$ 12-100 range directly. There was no requirement in the formulation of the computer model for Sr 100-400 apoB to be transferred into LDL. LDL apoB kinetics were described conventionally as a two pool system, the vascular compartment (pool 5) exchanging with an extravascular one. Capillary transfer rates between pools 5 and 6 were limited to maintain 72% of LDL apoB radioactivity in the plasma compartment in accordance with values obtained from studies of LDL kinetics (41, 42) . The fractional catabolic rate of LDL apoB is represented by k1o in Fig. 1 . * The product of calculated fractional catabolic rate and apoprotein pool size divided by body weight (in kilograms). This parameter, the absolute catabolic rate, equals the synthetic rate of the protein under steady state conditions. t The low level of apoB in this fraction precluded its accurate determination. The value quoted is an approximation. § Not significant. Packard et al. give a more detailed description of the situation in normal subjects (37) .
Effects of bezafibrate therapy on apoB metabolism. The above model produced the fractional clearance rates and apoB fluxes shown in Tables V, VI, VII, and VIII. In the control phase, Sf 100-400 VLDL apoB had a fractional clearance rate (7.0 pools/d) substantially slower than the value found in normal individuals (see reference 37). The absolute clearance rate of VLDL apoB in the hypertriglyceridemics was 11.6 mg/kg per d. On the average, one-third of this was removed directly and the remainder appeared in the Sf 12-100 flotation range. Bezafibrate administration lowered the mean plasma S$ 100-400 VLDL apoB concentration to 30% of its initial value primarily by promoting its catabolism (Fig. 4) . The mean residence time of the protein fell from 3.4 to 1.0 h, whereas its rate of synthesis remained constant. The biexponential decay of Sr 100-400 VLDL apoB which was seen in the Type V subjects in the control phase could be resolved to virtually a single exponential during bezafibrate therapy (see the profile for Type V subject VS in Fig. 4) .
In contrast to the S 100-400 VLDL apoB pool size which reflected mainly plasma triglyceride levels, the apoB concentration in the intermediate Sr 12-100 fraction varied less from subject to subject. In the control situation the mean residence (Table VII) .
Overall, there was a 30% increase in the plasma Sf 12-100 apoB pool size (P < 0.05) but for the reasons discussed above this rise could not be clearly attributed to altered synthesis or catabolism. In fact, it would be necessary to label and study this fraction directly to obtain this information. In the present group of hypertriglyceridemic subjects, the majority (70% with a threefold reduction in the mean residence time of S$ 100-400 VLDL apoB in the circulation (Table VI ; Fig. 4) . Overall, synthesis of the protein was not affected. Therefore, the fall in the VLDL apoB pool size derived from an improvement in the efficiency of the delipidation pathway. Examination of the VLDL apoB clearance curves in Type V subject VS before and during drug treatment (Fig. 4) suggested that, in addition to accelerating the transit of VLDL down the delipidation cascade, the drug also influenced the distribution of particles in the Sf 100-400 range. Initially, substantial amounts of material were found in VLDL apoB pool 2 (Table VI) which led to the biexponential appearance of the VLDL apoB clearance curve (Fig. 4) . On the drug, catabolism of VLDL apoB was monoexponential, and the requirement for pool 2 in the computer model was eliminated. In an earlier study we investigated the nature of d < 1.006 kg/liter VLDL apoB catabolism in Type V hyperlipoproteinemic subjects (31) . The initial rapid VLDL apoB decay that we observed was thought to represent true VLDL catabolism for two reasons. First, its disappearance was associated with the rise in LDL apoB radioactivity; and second, it was removed from the plasma at the same rate as simultaneously injected normal or Type IV VLDL. The slowly metabolized species appeared to have no counterpart in normal or Type IV VLDL but was seen in
Type III Sf 100-400 VLDL where chylomicron remnants are known to accumulate (see reference 37). We therefore concluded that it represented chylomicrons or their remnants in these subjects. If this is so, one interpretation of the result seen in Fig. 4 is that bezafibrate, by enhancing the efficiency of the normal VLDL delipidation pathway, prevents accumulation of the slowly metabolized chylomicrons.
The decreased residence time of apol in VLDL may be the result of a number of possible drug-induced changes. For example, it may derive from an alteration in the composition of newly synthesised VLDL. The association between apoB and triglyceride synthesis in VLDL is loose (40) . Therefore, since chlorophenoxyisobutyric acid derivative treatment is known to suppress plasma free fatty acid levels (12), it is possible that it may limit the availability of substrate for hepatic triglyceride production, leading to secretion of VLDL with reduced triglyceride content. The model used to analyze the transit of apoB from Sf 100-400 through Sf 12-100 to 0-12 gave a satisfactory fit to data obtained during both phases of the study and to decays observed for these lipoprotein classes in normals subjects (see reference 37) . The results differ significantly from those of previous studies using separations based on fixed-angle ultracentrifugation for reasons discussed in reference 37. Specifically, the clearance rate of intermediate lipoproteins of Sf 12-100 is slower than that seen in earlier investigations and the extent of transit into $r 0-12 is much less than would be predicted.
Our intention was to attempt to separate, metabolically distinct entities by use of the swinging bucket rotor flotation technique.
The finding that the observed catabolic rates of Sf 100-400 (44) . Therefore, whereas these enzymes may play a role in the conversion of Sf 12-100 remnants to LDL (54, 55) they seem not to be rate limiting. Preliminary observations from this laboratory (56) suggest that although in normal subjects chemical modification of the arginyl residues on Sf 100-400 lipoproteins does not alter their conversion to Sf 12-100 particles, it does delay subsequent catabolism of the latter to LDL. We interpreted this to mean that the rate determining step in the transformation of intermediate density lipoproteins (IDL) Treatment of hyperlipidemic subjects with bezafibrate or other clofibrate analogues produces a change in LDL which, though variable in its size and magnitude, is predictable on the basis of the subject's initial lipid levels (14) . As noted earlier, the response seen in normotriglyceridemic hypercholesterolemic subjects is a fall in LDL. This seems to derive from an increase in receptor-mediated catabolism of the lipoprotein apoprotein (15) . However, if the drug is administered to hypertriglyceridemic subjects, whose LDL cholesterol levels are often subnormal, the plasma concentration of this lipoprotein rises. A response of this kind was observed in several of the subjects examined here (Table I) . Kinetic (58) proposed that high VLDL levels predisposed to LDL hypercatabolism. By extrapolation, the bezafibrate-induced reduction in plasma VLDL might be expected to reduce the rate of LDL clearance, as we in fact observed.
Epidemiologic (59) and metabolic (60) studies have linked the metabolism of triglyceride-rich particles with that of HDL. Consequently, it is to be expected that a lowering of VLDL levels might perturb HDL. Bezafibrate raised HDL cholesterol (by 13%; P < 0.02) in the 11 hypertriglyceridemic subjects that we examined (Table I) . We probed the mechanism behind this effect in five of these (Study I). They did not show a rise in the levels of the major HDL apoproteins, A-I and A-II (Table  II) , nor did the drug affect the turnover of these proteins (Table IV) . However, we did observe a small but significant rise in HDL2 which may have derived from drug induced activation of lipoprotein lipase. During the process of lipolysis, this enzyme apparently releases surface components of VLDL (protein, free cholesterol, and phospholipid) into the HDL density range where they combine with resident particles to produce the larger, less dense HDL2 (61, 62) . However, the increment in HDL2 was modest relative to the marked fall in VLDL and may have been blunted through the drug's reported stimulatory effect on hepatic lipase (11) . According to the proposal of Nikkila et al. (63) , this enzyme may function to shuttle the components of HDL2 back into the HDL3 density range.
